Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo

Cancer Research

Volumn 65, Issue 16, 2005, Pages 7348-7355

  Tajeddine, Nicolas ^a   Gala, Jean Luc ^a   Louis, Magali ^a   Van Schoor, Monique ^a   Tombal, Bertrand ^a   Gailly, Philippe ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM BINDING PROTEIN; CALVASCULIN; CASPASE; CYCLIN DEPENDENT KINASE INHIBITOR; ENHANCED GREEN FLUORESCENT PROTEIN; HEAT SHOCK PROTEIN 27; PRAME ANTIGEN; PROTEIN P21; SMALL INTERFERING RNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL CYCLE; CELL DEATH; CELL FRACTIONATION; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LEUKEMIA; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; CASPASES; CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; CELL NUCLEUS; CHO CELLS; CRICETINAE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; HEAT-SHOCK PROTEINS; HELA CELLS; HUMANS; K562 CELLS; MICE; MICE, NUDE; NEOPLASM PROTEINS; RECOMBINANT FUSION PROTEINS; S100 PROTEINS; TRANSFECTION;

EID: 23844530817     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4011     Document Type: Article

References (22)

1. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2004.
2. Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
3. Greiner J, Ringhoffer M, Taniguchi M, et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 2004;108: 704-11.
4. Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002;133:118-23.
5. van Baren N, Chambost H, Ferrant A, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998;102:1376-9.
6. Steinbach D, Viehmann S, Zintl F, Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 2002;138:89-91.
7. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001;193;73-88.
8. de Longueville F, Surry D, Meneses-Lorente G, et al. Gene expression profiling of drug metabolism and toxicology markers using a low-density DNA microarray. Biochem Pharmacol 2002;64:137-49.
9. 2+-binding protein family. Genes Dev 1989;3: 1086-93.
10. Lukanidin EM, Georgiev GP. Metastasis-related mts1 gene. Curr Top Microbiol Immunol 1996;213: 171-95.
11. Mazzucchelli L. Protein S100A4: too long overlooked by pathologists? Am J Pathol 2002;160:7-13.
12. Bjornland K, Winberg JO, Odegaard OT, et al. S100A4 involvement in metastasis: deregulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in osteosarcoma cells transfected with an anti-S100A4 ribozyme. Cancer Res 1999;59: 4702-8.
13. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e g. acute leukemia. Crit Rev Oncol Hematol 2004;50:87-100.
14. Pazzaglia L, Ponticelli F, Magagnoli G, et al. Activation of metalloproteinases-2 and -9 by interleukin-1α in S100A4-positive liposarcoma cell line: correlation with cell invasiveness. Anticancer Res 2004;24:967-72.
15. Parker C, Whittaker PA, Usmani BA, Lakshmi MS, Sherbet GV. Induction of 18A2/mts1 gene expression and its effects on metastasis and cell cycle control. DNA Cell Biol 1994;13:1021-8.
16. Grigorian M, Andresen S, Tulchinsky E, et al. Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. J Biol Chem 2001;276: 22699-708.
17. Garrido C, Schmitt E, Cande C, et al. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle 2003;2:579-84.
18. Kasimir-Bauer S, Ottinger H, Meusers P, et al. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy. Exp Hematol 1998;26: 1111-7.
19. Cartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-49.
20. Munker R, Zhang W, Elstner E, Koeffler HP. Vitamin D analogs, leukemia and WAF1. Leuk Lymphoma 1998;31:279-84.
21. Zhang W, Kornblau SM, Kobayashi T, et al. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res 1995;1:1051-7.
22. Schepers H, Geugien M, Eggen BJ, Vellenga E. Constitutive cytoplasmic localization of p21(Waf1/ Cip1) affects the apoptotic process in monocytic leukaemia. Leukemia 2003;17:2113-21.